Press Releases

20-12-2022

Change in the Supervisory Board of Eckert & Ziegler AG

19-12-2022, 13:29 CET (Ad hoc press release)

Changes in the Management Board of Eckert & Ziegler

25-11-2022, 15:36 CET (Ad hoc press release)

Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR

08-11-2022

​​​​​​​Eckert & Ziegler: Nine-Month Figures Show Strong Sales Growth

27-10-2022

First CNS Lymphoma Patient Imaged with PentixaFor in Phase 2 Trial

13-10-2022

Eckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement

11-10-2022

Eckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility

11-08-2022

​​​​​​​Eckert & Ziegler with Successful First Half of 2022

04-08-2022

Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures

27-07-2022, 12:53 CEST (Ad hoc press release)

Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter

21-07-2022

Eckert & Ziegler Affiliate Receives Further NIAID Funding for Clinical Development

20-07-2022

Eckert & Ziegler and PRECIRIX Sign Agreement on Priority Supply of the Therapeutic Radioisotope Actinium-225 (Ac-225)

06-07-2022

Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225

05-07-2022, 13:08 CEST (Ad hoc press release)

Eckert & Ziegler Lowers 2022 Profit Guidance to 27 mm EUR

12-05-2022

Eckert & Ziegler with Sales Growth in the First Quarter of 2022

11-05-2022

Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Alpha Radioisotopes

08-04-2022

Eckert & Ziegler: Radboud University Medical Center Netherlands to Image First Patient with PENTIXAFOR

06-04-2022, 19:52 CEST (Ad hoc press release)

​​​​​​​Eckert & Ziegler Publishes Preliminary Figures for Q1/2022 with Deviation in Earnings and Confirms Annual Forecast for 2022

30-03-2022

Eckert & Ziegler with Record Results in FY 2021 and Positive Outlook

24-03-2022, 19:16 CET (Ad hoc press release)

Eckert & Ziegler to Increase Dividend Proposal

23-03-2022

Eckert & Ziegler to Supply Canadian Alpha-9 Theranostics with Lutetium-177 for Clinical Trials

22-03-2022

Eckert & Ziegler Extends Supply Agreement with Sirtex Medical to Chinese Market

09-02-2022

Eckert & Ziegler to Supply Telix with Lutetium-177 for Clinical Trials

10-01-2022, 19:36 CET (Ad hoc press release)

​​​​​​​Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176

03-01-2022, 16:50 CET (Ad hoc press release)

​​​​​​​Eckert & Ziegler Acquires Argentinian SPECT Specialist